Zai Lab says partner Novocure’s Phase 3 trial met primary endpoint

Zai Lab (ZLAB) said its partner Novocure (NVCR) announced the Phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer following stereotactic radiosurgery. Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis . Preliminary analyses of key secondary endpoints did not demonstrate statistical significance. Novocure intends to submit these data to regulatory authorities. Zai Lab said it contributed to the METIS trial and achieved treatment of the first patient in Greater China in May 2021.